Harnessing Artificial Intelligence-driven Approaches in the Diagnosis and Management of Diabetes and Diabetes-Associated Complications.

IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM
Yachana Mishra, Rajeev Kanday, Simran Kauts, Sheetu Wadhwa, Aditi Chattaraj, Alaa A A Aljabali, Altijana Hromić-Jahjefendić, Vladimir N Uversky, Vijay Mishra
{"title":"Harnessing Artificial Intelligence-driven Approaches in the Diagnosis and Management of Diabetes and Diabetes-Associated Complications.","authors":"Yachana Mishra, Rajeev Kanday, Simran Kauts, Sheetu Wadhwa, Aditi Chattaraj, Alaa A A Aljabali, Altijana Hromić-Jahjefendić, Vladimir N Uversky, Vijay Mishra","doi":"10.2174/0115733998484763260928100503","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes mellitus is a global health issue with escalating metabolic dysfunction, clinical heterogeneity, and rising microvascular and macrovascular consequences. Traditional diabetes diagnosis, risk assessment, treatment selection, and complication surveillance rely on periodic clinical measures and population-level risk models, which may not fully capture dynamic, individualized disease pathways. Precision diabetes treatment is being transformed by Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and multimodal data analytics. This review critically examines AI-driven approaches to diabetes management, including early disease prediction, diagnostic support, glycemic monitoring, treatment-response prediction, and the prevention and detection of diabetes-associated complications. The US Food and Drug Administration (USFDA) has sanctioned multiple AI/ML-based medical devices for automated retinal screening, clinical diagnostic assistance, and patient self-management applications. For clinically meaningful patterns and disease progression prediction, AI-enabled analysis of continuous glucose monitoring data, retinal images, electronic health records, wearable device signals, laboratory parameters, and multi-omics datasets is prioritized. The use of AI for detecting diabetic retinopathy, kidney disease, cardiovascular disease, neuropathy, and foot disorders is also highlighted.Data quality, algorithmic bias, interpretability, privacy, cybersecurity, model drift, regulatory monitoring, clinical validation, and equitable access prevent widespread application despite promising results. This study offers a thorough and critical assessment of the developing roles of AI, specifically ML and DL, in the prediction, diagnosis, and management of diabetes and its related complications. Real-world validation, standardized evaluation frameworks, trustworthy AI, and effective human- AI collaboration will drive advancement. AI could transform diabetes management into predictive, tailored, continuous, and complication-preventive care.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733998484763260928100503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes mellitus is a global health issue with escalating metabolic dysfunction, clinical heterogeneity, and rising microvascular and macrovascular consequences. Traditional diabetes diagnosis, risk assessment, treatment selection, and complication surveillance rely on periodic clinical measures and population-level risk models, which may not fully capture dynamic, individualized disease pathways. Precision diabetes treatment is being transformed by Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and multimodal data analytics. This review critically examines AI-driven approaches to diabetes management, including early disease prediction, diagnostic support, glycemic monitoring, treatment-response prediction, and the prevention and detection of diabetes-associated complications. The US Food and Drug Administration (USFDA) has sanctioned multiple AI/ML-based medical devices for automated retinal screening, clinical diagnostic assistance, and patient self-management applications. For clinically meaningful patterns and disease progression prediction, AI-enabled analysis of continuous glucose monitoring data, retinal images, electronic health records, wearable device signals, laboratory parameters, and multi-omics datasets is prioritized. The use of AI for detecting diabetic retinopathy, kidney disease, cardiovascular disease, neuropathy, and foot disorders is also highlighted.Data quality, algorithmic bias, interpretability, privacy, cybersecurity, model drift, regulatory monitoring, clinical validation, and equitable access prevent widespread application despite promising results. This study offers a thorough and critical assessment of the developing roles of AI, specifically ML and DL, in the prediction, diagnosis, and management of diabetes and its related complications. Real-world validation, standardized evaluation frameworks, trustworthy AI, and effective human- AI collaboration will drive advancement. AI could transform diabetes management into predictive, tailored, continuous, and complication-preventive care.

利用人工智能驱动的方法诊断和管理糖尿病和糖尿病相关并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书